BlueCare, the deepTech applied to microalgae
BlueCare Discovery, a biotech startup, targets the best marine active ingredients by providing scientific evidence and clinical studies.
We can talk about real cellular factories capable of sustainably producing the active ingredients of tomorrow.
Among the molecules of interest for the industry, there are :
isoprenoids (chlorophylls, carotenoids)
fatty acids and their derivatives
An underexploited biological activity potential
Due to their biochemical reactivity, some of these molecules have the ability to interfere with biological targets and thus with pathophysiological pathways.
They have the potential to become biopharmaceutical leads addressing therapeutic needs that are not met by the current pharmacopeia.
Active ingredients dedicated to 5P precision medicine
Thanks to recent developments in early biomarkers, it will be possible to predict the onset of chronic diseases that can be very debilitating, up to 20 years before the appearance of the first symptoms.
By consuming preventive agents before the disease becomes complex, it is possible to delay, limit or even prevent the onset of the disease.
This approach leads patients to be aware and responsible for their health capital, to be proactive in their preventive and possibly therapeutic care.
The future of medicine is clearly moving towards highly personalized solutions for the patient (genetic data, biochemical deficiencies). This integrative approach allows for a more targeted, safe, and effective prescription.
Precision & Evidence
Clinical studies validate the efficacy of the active compounds developed, and patient follow-up confirms the improvement in health status.
A marine biotech platform
Based on years of cutting-edge research in marine pharmacognosy, our BluepulseTM bioplatform has a high technological intensity.
Its purpose is to drastically reduce the time and investment required for the discovery and development of new health actives.
A derisked and ambitious pipeline
The neurodegenerative sphere
The applications related to neuron degeneration are numerous: cognitive decline, Alzheimer’s, Parkinson’s, schizophrenia, etc.
Our most promising current lead, BCD-s1184, is in the preclinical study phase. Due to its polypharmacological action, our current mission is to clarify the original (first-in-class) therapeutic targets it affects.
A pipeline with high potential
Our bioplatform, designed to accelerate and secure developments beyond traditional discovery strategies, has enabled us to identify hits in a variety of application areas.
The ageing of the world’s population, our (too) extreme lifestyles, chronic stress, the presence of endocrine disruptors and other pollutants in our environment and diet, are all contributing to the emergence of numerous metabolic diseases.
BlueCare Discovery aims to meet the health solution needs that are still unmet, ineffective, or unsafe.
Our R&D partners
BlueCare’s success depends on partnerships with the best private and public research teams in the field. We work with :